EUCTR2004-004948-45-ES进行中（未招募）不适用
Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks more of treatment in patients with chronic hepatitis C genotype 1 and/or 4 co-infected with human inmmunodeficiency virus - Treatment of co-infected HIV/HCV patients genotype 1/4 24 weeks more than standar duration
José Hernández-Quero. Hospital Clínico San Cecilio0 个研究点开始时间: 2006年5月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients in treatment with peginterferon alfa-2a and ribavirin which HCV-RNA is undetectable at 48 weeks.
- •- Patients with RNA-HCV positive and genotype 1/4 at 44 weeks before the start of study.
- •- HIV positive
- •- AIDS stable
- •- Pregnancy test negative
- •- Patient authorization to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with HCV-RNA positive after 44 weeks of treatment with peginterferon alfa-2a in combination with ribavirin
- •- Patients with other different treatment to the study.
- •- 3 o more weeks without treatment between the end of the standard treatment and the inclusion in the trial.
研究者
相似试验
进行中（未招募）
不适用
24 weeks vs. 48 weeks of treatment of coinfected HIV/HCV patients genotype II-IIIHepatitis CEUCTR2005-000203-34-ESEnrique Ortega González186
进行中（未招募）
不适用
Open, multicenter and randomized phase IV trial to evaluate the viral kinetic during 12 first weeks of patients with chronic hepatitis C genotype 1 and 4 coinfected with HIV treated with induction doses of peginterferon alfa 2a (270 mcg/week) and ribavirin (1600 mg/day) with the support of epoetin beta (450 UI/kg/week) - Study of viral kinetic of HCV in HIV patientsChronic hepatitis CEUCTR2004-000907-16-ESBonaventura Clotet/Ramón Planas/Ricard Solá
进行中（未招募）
1 期
A study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in HIV+ patients.EUCTR2019-000199-41-ESFundación SEIMC-GESIDA234
进行中（未招募）
不适用
Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)EUCTR2005-001026-89-DESerono GmbH100
已完成
不适用
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24PER-019-04BRISTOL MYERS SQUIBB COMPANY,